Recruiting Ulcerative Colitis Studies in Lancaster
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Parti...
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficac...
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and ef...
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately...
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Coli...
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with mo...
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treate...
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with m...
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will comp...
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC)....
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis (ROSETTA)
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)...
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compare...
About Ulcerative Colitis Clinical Trials in Lancaster
Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the innermost lining of the colon and rectum. It typically presents with bloody diarrhea, abdominal pain, and urgency. Treatment includes aminosalicylates, corticosteroids, immunosuppressants, and biologics.
There are currently 12 ulcerative colitis clinical trials recruiting participants in Lancaster, SOUTH%20CAROLINA. These studies are seeking a combined 4,313 participants. Research is being sponsored by Eli Lilly and Company, Spyre Therapeutics, Inc., AbbVie and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ulcerative Colitis Clinical Trials in Lancaster — FAQ
Are there ulcerative colitis clinical trials in Lancaster?
Yes, there are 12 ulcerative colitis clinical trials currently recruiting in Lancaster, SOUTH%20CAROLINA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lancaster?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lancaster research site will contact you about next steps.
Are clinical trials in Lancaster free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lancaster studies also compensate for your time and travel.
What ulcerative colitis treatments are being tested?
The 12 active trials in Lancaster are testing new therapies including novel drugs, biologics, and treatment approaches for ulcerative colitis.
Data updated March 2, 2026 from ClinicalTrials.gov